Showing results (1001-1010 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 30, 2011
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytesJoanna Edyta Fraczek, Mathieu Vinken, Dirk Tourwé, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
Investigational New Drugs|June 10, 2011
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in miceMohammad Abolhassani, Adeline Guais, Edward Sanders, et al.
Investigational New Drugs|June 10, 2011
Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatinElisabetta Buommino, Anna De Filippis, Rosario Nicoletti, et al.
Investigational New Drugs|November 4, 2011
(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9Christian Freise, Wolfram Trowitzsch-Kienast, Martin Ruehl, et al.
Investigational New Drugs|November 1, 2011
Sorafenib exposure decreases over time in patients with hepatocellular carcinomaJennifer Arrondeau, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Investigational New Drugs|October 12, 2011
Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC)George R Blumenschein
Investigational New Drugs|October 19, 2011
Continuing pursuit for ideal systemic anticancer radiotherapeuticsMarlein Miranda Cona, Huaijun Wang, Junjie Li, et al.
Investigational New Drugs|October 19, 2011
Saturable absorption of sorafenib in patients with solid tumors: a population modelMarilyne Hornecker, Benoit Blanchet, Bertrand Billemont, et al.
Investigational New Drugs|November 15, 2011
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combinationMichael Millward, Timothy Price, Amanda Townsend, et al.
Pageof 372